Analysis of the clinical characteristics of pembrolizumab-induced bullous pemphigoid

BACKGROUND: Pembrolizumab, a programmed cell death protein 1 checkpoint inhibitor, is a novel drug used to treat a variety of advanced malignancies. However, it can also result in many immune-related adverse events, with cutaneous toxicities being the most frequent. Regarding pembrolizumab-induced s...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jianglin, Hu, Xin, Jiang, Wei, Zhou, Wenjie, Tang, Mengjie, Wu, Cuifang, Liu, Wei, Zuo, Xiaocong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022695/
https://www.ncbi.nlm.nih.gov/pubmed/36937423
http://dx.doi.org/10.3389/fonc.2023.1095694

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022695/
https://www.ncbi.nlm.nih.gov/pubmed/36937423
http://dx.doi.org/10.3389/fonc.2023.1095694

Ejemplares similares